Left Ventricular Hypertrophy
Total Page:16
File Type:pdf, Size:1020Kb
Evaluation of Subclinical Target Organ Damage for Risk Assessment and Treatment in the Hypertensive Patients: Left Ventricular Hypertrophy Enrico Agabiti-Rosei, Maria Lorenza Muiesan, and Massimo Salvetti Internal Medicine, University of Brescia, Brescia, Italy At some point in the natural history of hypertension, the compensatory increase in left ventricular mass ceases to be beneficial. Left ventricular hypertrophy (LVH) becomes a preclinical disease and an independent risk factor for congestive heart failure, ischemic heart disease, arrhythmia, sudden death, and stroke. In addition to elevated BP, several mechanisms are involved, including body size, age, gender, race, fibrogenic cytokines, and neurohumoral factors, notably angiotensin II, which favor interstitial collagen deposition and perivascular fibrosis. These tissue changes are responsible for the insidious contractile dysfunction that is associated with LVH, consequent to decreased coronary reserve and altered diastolic ventricular filling and relaxation. The cardinal investigations are echocardiography and electrocardiography. All antihypertensive drugs regress LVH, notably those that act on the renin-angiotensin-aldosterone system, which also could target the detrimental tissue changes. Regression enhances systolic midwall performance, normalizes autonomic function, and restores coronary reserve. The resulting improvement in prognosis has enshrined the detection, prevention, and reversal of LVH in the current guidelines of hypertension management. J Am Soc Nephrol 17: S104–S108, 2006. doi: 10.1681/ASN.2005121336 t some point in the natural history of hypertension, hemodynamic load, echocardiographic LVM could be assessed the compensatory increase in left ventricular mass in the individual patient as deviation from the value that is A (LVM) is not beneficial anymore. In fact, it becomes a appropriate for a given cardiac workload, corrected for gender preclinical disease and an independent risk factor for conges- and body size. LVM that overcompensates for hemodynamic tive heart failure, ischemic heart disease, arrhythmia, sudden load tends to cluster with metabolic risk factors and is associ- death, and stroke (1). ated with high cardiovascular risk (6,7). The definition and the clinical evaluation of “inappropriate” LVM require further Determinants of Hypertensive Left study. Ventricular Hypertrophy Among the main nonhemodynamic factors that may contrib- The high prevalence of LV hypertrophy (LVH) in hyperten- ute to the development of LVH, a variety of neurohumoral and sion reflects the increased afterload imposed on the left ventri- growth factors (e.g., catecholamines, angiotensin II [AngII], al- cle, although other important determinants are demographic dosterone, endothelins) are included. The effect of sympathetic characteristics (e.g., age, gender, race), neurohumoral and nervous system activity is evident in experimental models but growth factors, and underlying genetic factors. Hypertension is less clear-cut in humans: in pheochromocytoma LVH preva- the fundamental trigger to the sequence of biologic events that lence is relatively low and LVM seems to increase proportion- lead to the development of LVH. LVM is more closely related ately to BP, then in essential hypertension, LVH is associated to average 24-h BP (2–4). Volume load, inotropy, and arterial with altered autonomic activity and a blunted response to compliance also are important determinants of the develop- -adrenoceptor stimulation (8–10). Experimental studies also ment and the degree of LVH. Other contributing factors include highlighted the role of the renin-angiotensin-aldosterone sys- stage of hypertensive disease, genetics, demographic factors, tem (RAAS) in mediating LVH (11,12). AngII induces hyper- comorbid diseases (e.g., diabetes, obesity, coronary artery dis- trophy and hyperplasia in myocytes and vascular smooth mus- ease), possibly mediated via cardiac load. Obesity, which com- cle cells and may regulate collagen synthesis. Excess AngII pounds hemodynamic load independent of a clear-cut increase production may regulate the expression of fibrogenic cytokine in BP, is a major determinant of LVM, because it is associated TGF-1 and favor perivascular and interstitial fibrosis. In ad- with increased plasma volume and cardiac output (5). It has dition, AngII may interfere with the process of collagen degra- been suggested that considering these measurable factors and dation, modulating the activity of metalloproteinases (a family of zinc-containing proteins that include stromelysins, collag- enases, and gelatinases) and their inhibitors (12). Aldosterone Address correspondence to: Prof. Enrico Agabiti-Rosei, Internal Medicine, Med- also may stimulate extracellular collagen deposition and myo- ical and Surgical Sciences, University of Brescia, c/o 2a Medicina Spedali Civili di Brescia, Piazza Spedali Civili 1, 25100 Brescia, Italy. Phone: ϩ30-396044; Fax: cardial fibrosis. ϩ30-3388147; E-mail: [email protected] The pathogenic role of the RAAS in the development of Copyright © 2006 by the American Society of Nephrology ISSN: 1046-6673/1704-0104 J Am Soc Nephrol 17: S104–S108, 2006 Pathophysiology and Treatment of Hypertensive LVH S105 hypertensive LVH requires confirmation, although LVM is sig- more expensive or time-consuming and are still of limited nificantly increased in renovascular hypertension and primary availability. aldosteronism compared with essential hypertension (13,14). Methods have been developed to quantify tissue composi- Increased activity of the RAAS and sympathetic nervous sys- tion. Studies in animals and humans have shown that LV tem, hypervolemia, and anemia all may influence the increase acoustic properties under physiologic and pathologic condi- of LVM in patients with renal disease. tions are influenced by several tissue components (myocar- Hypertensive LVH often is associated with insulin resistance dium, contractile and elastic tissue, collagen and inelastic tis- and high insulin levels (15). The involvement of IGF- I could sue, arteries, veins, myocytes, and sarcomeres). Results with clarify the link among obesity, BP elevation, LVH, and the videodensitometry and integrated backscatter to characterize metabolic syndrome. Leptin is another possible neuroendocrine tissue in several diseases that are associated with abnormal determinant. LVH in an animal model of leptin deficiency (the myocardial tissue, including hypertensive LVH and diabetes, ob/ob mouse) reversed rapidly in response to exogenous leptin, indicate that these techniques can complement clinical evalua- therefore indicating the involvement of myocardial leptin re- tion by revealing preclinical end-organ damage (25,26). Further ceptors in cardiac remodeling (16). Other major metabolic car- reproducibility and feasibility studies are required to assess the diovascular risk factors, notably hypercholesterolemia and hy- clinical applications of these techniques. perglycemia, also may have an influence on LVM and the prevalence of LVH (17). Prognostic Significance of LVH Several studies have suggested that approximately 30% of Whether assessed by ECG or echocardiography, LVH is a LVM variance is genetically determined (18). Studies of genetic well-documented harbinger of morbidity and mortality. In sev- influence on LVM have focused mainly and are ongoing on the eral studies, the adjusted risk for cardiovascular morbidity role of candidate genes, including those that are related to the associated with baseline LVH ranges from 1.5 to 3.5 with a RAAS, ␣- and -adrenoceptors, and components of the signal weighted risk ratio of 2.3 for all studies combined (27). Con- transduction mechanisms involved in cardiac hypertrophy. centric hypertrophy seems to carry the highest risk and eccen- tric hypertrophy an intermediate risk, whereas concentric re- modeling is probably associated with a smaller, albeit Methods of Assessing LVH noteworthy, risk. As recommended by the European Society of Hypertension The structural remodeling of cardiomyocytes, nonmyocytes, and European Society of Cardiology (19), LVH is diagnosed and fibroblasts that occurs in cardiac hypertrophy contributes most commonly using electrocardiography (ECG) and M-mode to perivascular fibrosis, initially around intramural coronary and two-dimensional echocardiography. New ECG criteria in arteries and thereafter in the interstitial space, leading to pro- addition to repolarization abnormalities and increased voltage gressive abnormalities of diastolic ventricular filling and relax- have been proposed, the Cornell method probably being the ation, systolic dysfunction, arrhythmias, and conduction dis- most sensitive (20). The ECG also can be used to detect patterns turbances, thereby greatly compounding the risk that is of ventricular overload (“strain”) or ischemia, which indicate associated with LVH (1). higher cardiovascular risk. ECG and echocardiographic LVH The resulting pathophysiologic and clinical changes that ac- both predict mortality independent of each other and other count for increased risk in hypertensive LVH include both cardiovascular risk factors, thus conveying, at least in part, diastolic and systolic dysfunction. LVH and failure are fre- different prognostic information (21,22). Echocardiography has quently associated with coronary artery disease, and hyperten- some advantages because it provides comprehensive wall, sion is a major risk factor for coronary atherosclerosis. In ECG chamber, and LVM measures, together